Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 7/20 | 0.51 |
| ▸ | S1PR1 | P21453 | 3/20 | 0.43 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.43 |
| ▸ | THRA | P10827 | 5/20 | 0.38 |
| ▸ | PPARG | P37231 | 2/20 | 0.37 |
| ▸ | PPARA | Q07869 | 2/20 | 0.37 |
| ▸ | PPARD | Q03181 | 1/20 | 0.37 |
| ▸ | EIF4A1 | P60842 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | MAOA | P21397 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.36 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.35 |
| ▸ | ACHE | P22303 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23395719 | 0.92 | THRB (0.48) | THRBS1PR1S1PR3THRAPPARG | |
| SCHEMBL24595652 | 0.91 | THRB (0.47) | THRBMEN1KMT2AMAOAMAOB | |
| SCHEMBL25901437 | 0.90 | THRB (0.52) | THRBS1PR1S1PR3THRAPPARG | |
| SCHEMBL23395688 | 0.89 | THRB (0.44) | THRBS1PR1S1PR3THRAPPARG | |
| SCHEMBL23395672 | 0.87 | THRB (0.41) | THRBS1PR1S1PR3THRAPPARG | |
| SCHEMBL23893543 | 0.87 | THRB (0.42) | THRBS1PR1S1PR3THRAPPARG | |
| SCHEMBL23395629 | 0.86 | THRB (0.40) | THRBS1PR1S1PR3THRAPPARG | |
| SCHEMBL14618503 | 0.85 | THRB (0.60) | THRBTHRAPPARAMEN1KMT2A | |
| SCHEMBL23395676 | 0.85 | HDAC6 (0.42) | S1PR1S1PR3MEN1KMT2AMAOB | |
| SCHEMBL23893634 | 0.83 | S1PR1 (0.45) | THRBS1PR1S1PR3PPARGPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11753387-B2 | Compounds for optically active devices | Johnson & Johnson Surgical Vision, Inc. (US) | 2023-09-12 | — | — | US | disclosed |
| EP-3889135-B1 | COMPOUNDS FOR OPTICALLY ACTIVE DEVICES | AMO Ireland (IE) | 2023-08-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11753387-B2 | Compounds for optically active devices | PDE6C, PDE6A, PDE6D | THRB 4502/4885S1PR1 3832/4885S1PR3 2612/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.